Neurocrine Biosciences, Inc. (NBIX): Price and Financial Metrics

NBIX POWR Grades

• Quality is the dimension where NBIX ranks best; there it ranks ahead of 96.4% of US stocks.
• The strongest trend for NBIX is in Value, which has been heading up over the past 179 days.
• NBIX ranks lowest in Momentum; there it ranks in the 32nd percentile.

NBIX Stock Summary

• NBIX has a higher market value than 83.51% of US stocks; more precisely, its current market capitalization is $9,190,339,732.
• With a price/earnings ratio of 59.48, NEUROCRINE BIOSCIENCES INC P/E ratio is greater than that of about 91.21% of stocks in our set with positive earnings.
• With a year-over-year growth in debt of -40.3%, NEUROCRINE BIOSCIENCES INC's debt growth rate surpasses only 7.12% of about US stocks.
• If you're looking for stocks that are quantitatively similar to NEUROCRINE BIOSCIENCES INC, a group of peers worth examining would be MRAM, PDEX, NSPR, SONO, and CLPT.
• Visit NBIX's SEC page to see the company's official filings. To visit the company's web site, go to www.neurocrine.com.

NBIX Valuation Summary

• NBIX's price/sales ratio is 6.1; this is 221.05% higher than that of the median Healthcare stock.
• NBIX's EV/EBIT ratio has moved up 55.2 over the prior 243 months.

Below are key valuation metrics over time for NBIX.

NBIX Growth Metrics

Its 3 year price growth rate is now at 15.15%.
• The year over year net cashflow from operations growth rate now stands at -53.64%.
• Its 3 year net cashflow from operations growth rate is now at 370.41%.

Over the past 52 months, NBIX's revenue has gone up $1,074,435,000.

The table below shows NBIX's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-12-31	1,488.7	339.4	154.5
2022-09-30	1,388.7	200.6	58.2
2022-06-30	1,296.8	163.6	12.2
2022-03-31	1,207.5	128.7	71.4
2021-12-31	1,133.5	256.5	89.6
2021-09-30	1,069.4	341.2	444.8

NBIX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• NBIX has a Quality Grade of B, ranking ahead of 78.08% of graded US stocks.
• NBIX's asset turnover comes in at 0.566 -- ranking 66th of 682 Pharmaceutical Products stocks.
• LGND, MNKD, and MRK are the stocks whose asset turnover ratios are most correlated with NBIX.

The table below shows NBIX's key quality metrics over time.